<DOC>
	<DOCNO>NCT01999725</DOCNO>
	<brief_summary>The primary objective study determine safety single dos orally administer EDP-788 . Secondary objective study : - To describe pharmacokinetics EDP-788 ( metabolite EDP-322 ) single dos orally administer drug - To estimate bioavailability EDP-788 capsule relative oral liquid suspension - To estimate effect co-administration food absorption EDP-788</brief_summary>
	<brief_title>Evaluation Safety Pharmacokinetics Single Oral Dose EDP-788</brief_title>
	<detailed_description>Subjects enrol successive cohort randomize receive either EDP-788 placebo capsule . If safety profile drug acceptable , base upon review blind data , cohort receive next high dose treat . Up 8 cohort recruit . All subject receive single dose study drug ( EDP-788 placebo ) . Subjects Cohort C receive second single dose study drug ( EDP-788 placebo ) approximately 2 week first dose . The second dose administer liquid suspension rather capsule formulation . The purpose second dose estimate bioavailability capsule formulation relative suspension . Subjects Cohort E receive second single dose study drug ( EDP-788 placebo ) approximately 2 week first . The second dose administer standard test meal . The purpose second dose estimate effect food absorption EDP-788 .</detailed_description>
	<criteria>Key In good general health BMI 18 32 kg/m2 Women must nonchildbearing potential ( surgically sterilize ) Normal electrocardiogram Willing abstain strenuous physical exercise start 3 day prior admission study clinic 8 10 day postdosing visit Key Hypersensitivity macrolide antibiotic Abnormal laboratory value History gastrointestinal surgery may interfere drug absorption Active Hepatitis B , Hepatitis C , HIV infection Use prescription nonprescription drug within 14 day study drug administration Use nicotine within 3 month study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Normal Volunteers , Safety , Pharmacokinetics</keyword>
</DOC>